HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAapproval84% confidence

Withdrawn | Cancer Accelerated Approvals

Source: FDA

Why This Matters

Why this matters: sets a approval precedent in the same sub-indication (pain) as Dr. Reddy's Labs; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.

Supporting Context

Therapeutic area
Addiction · Opioid Dependence
Sub-indication
Pain

Related signal: FDA Approval Update for Buprenorphine and Naloxone from Dr. Reddy's Labs

Source

View source document

Related Signal

Open signal — FDA Approval Update for Buprenorphine and Naloxone from Dr. Reddy's Labs
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.